Table 2.

Clinical features and outcomes of kidney transplant recipients with COVID-19

Clinical Features and OutcomesAll Patients, n=66Invasive Mechanical Ventilation, n=15No Invasive Mechanical Ventilation, n=51
Features at diagnosis
 Clinical presentation, no. (%)
  Fever51 (77)12 (80)39 (76)
  Cough38 (58)11 (73)27 (53)
  Dyspnea (exertional or rest)26 (39)12 (80)14 (27)
  Diarrhea17 (26)2 (13)15 (29)
  Anosmia/ageusia7 (11)0 (0)7 (14)
 Laboratory testsa
  White blood cell count, 1000/µl, median (range)a5.9 (1.6–14.2)7.4 (2.6–14.2)5.3 (1.6–13.2)
  Absolute lymphocyte count, /µl528 (80–1300)473 (80–1180)548 (169–1300)
  C-reactive protein, mg/L115 (0–335)159 (18–316)96 (0–335)
 Chest x-ray/pulmonary CT scan,a no. (%)
  Multifocal/bilateral patchy opacities38/56 (68)12/13 (92)26/43 (60)
  Lobar opacities3/56 (5)1/13 (8)2/43 (5)
  No acute findings15/56 (27)0/13 (0)15/43 (35)
 Immunosuppressive treatment, no. (%)
  MMF/MPA/AZA61 (92)13 (87)48 (94)
  CNI57 (86)14 (93)43 (84)
  Belatacept6 (9)1 (7)5 (10)
  Steroids55 (83)13 (87)42 (82)
Treatment and outcome
 Change in immunosuppression, no. (%)
  Discontinued only MMF/MPA/AZA38/61 (62)13 (100)25/48 (52)
  Discontinued only CNI2/57 (4)2/14 (14)0
  Belatacept infusion postpone1/6 (17)01/5 (20)
  No change24 (36)2 (13)22 (43)
  Discontinued all immunosuppression1 (2)1 (7)0
 Anti–COVID-19 therapies, no. (%)
  Hydroxychloroquine7 (11)4 (27)3 (6)
  Tocilizumab1 (2)0 (l0)1 (2)
  Eculizumab2 (3)0 (0)2 (4)
 Outcomes, no. (%)
  AKI28 (42)13 (87)15 (29)
  RRT required7 (11)7 (47)0 (0)
  Died16 (24)11 (73)5 (10)
  Recovery50 (76)4 (27)46 (90)
  • Data are displayed as n (%) or median (range). CT, computed tomography; MMF, mycophenolate mofetil; MPA, mycophenolic acid; AZA, azathioprine; CNI, calcineurin inhibitor.

  • a Data recorded in the 60 hospitalized patients, with missing data for two patients in the invasive mechanical ventilation group and two patients in the noninvasive mechanical ventilation group, for patients admitted to other hospitals.